A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.

Young-Ah Suh, Jai-Hyun Kim, Myung A Sung, Hye-Jin Boo, Hye Jeong Yun, Sun-Hye Lee, Hyo-Jong Lee, Hye-Young Min, Young-Ger Suh, Kyu-Won Kim, Ho-Young Lee

Index: Cancer Lett. 332(1) , 102-9, (2013)

Full Text: HTML

Abstract

In this study, we investigated the antitumor effects of deguelin in several human breast cancer cells in vitro and in vivo. Deguelin inhibited cell viability and the anchorage-dependent and anchorage-independent colony formation of triple-negative (MDA-MB-231 and MDA-MB-468) and triple-positive (MCF-7) breast cancer cells, and it significantly reduced the growth of MCF-7 cell xenograft tumors. The induction of apoptosis, inhibition of insulin-like growth factor-1 receptor (IGF-1R) signaling activation, and up-regulation of IGF-binding protein-3 (IGFBP-3) expression may be associated with deguelin-mediated antitumor effects. Our findings suggest a potential therapeutic use for deguelin in patients with triple-negative breast cancer and for those with breast cancers who are sensitive to endocrine- and HER2-targeted therapies.Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.